Literature DB >> 12466357

Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance.

Robert C Andrews1, Olive Herlihy, Dawn E W Livingstone, Ruth Andrew, Brian R Walker.   

Abstract

Recent evidence suggests that increased cortisol secretion, altered cortisol metabolism, and/or increased tissue sensitivity to cortisol may link insulin resistance, hypertension, and obesity. Whether these changes are important in type 2 diabetes mellitus (DM) is unknown. We performed an integrated assessment of glucocorticoid secretion, metabolism, and action in 25 unmedicated lean male patients with hyperglycemia (20 with type 2 diabetes and 5 with impaired glucose intolerance by World Health Organization criteria) and 25 healthy men, carefully matched for body mass index, age, and blood pressure. Data are mean +/- SE. Patients with hyperglycemia (DM) had higher HbA(1c) (6.9 +/- 0.2% vs. 6.0 +/- 0.1%, P < 0.0001) and triglycerides. Cortisol secretion was not different, as judged by 0900 h plasma cortisol and 24 h total urinary cortisol metabolites. However, the proportion of cortisol excreted as 5alpha- and 5beta-reduced metabolites was increased in DM patients. Following an oral dose of cortisone 25 mg, generation of plasma cortisol by hepatic 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD 1) was impaired in DM patients (area under the curve, 3617 +/- 281 nM.2 h vs. 4475 +/- 228; P < 0.005). In contrast, in sc gluteal fat biopsies from 17 subjects (5 DM and 12 controls) in vitro 11beta-HSD 1 activity was not different (area under the curve, 128 +/- 56% conversion.30 h DM vs. 119 +/- 21, P = 0.86). Sensitivity to glucocorticoids was increased in DM patients both centrally (0900 h plasma cortisol after overnight 250 micro g oral dexamethasone 172 +/- 16 nM vs. 238 +/- 20 nM, P < 0.01) and peripherally (more intense forearm dermal blanching following overnight topical beclomethasone; 0.56 +/- 0.92 ratio to vehicle vs. 0.82 +/- 0.69, P < 0.05). In summary, in patients with glucose intolerance, cortisol secretion, although normal, is inappropriately high given enhanced central and peripheral sensitivity to glucocorticoids. Normal 11beta-HSD 1 activity in adipose tissue with impaired hepatic conversion of cortisone to cortisol suggests that tissue-specific changes in 11beta-HSD 1 activity in hyperglycemia differ from those in primary obesity but may still be susceptible to pharmacological inhibition of the enzyme to reduce intracellular cortisol concentrations. Thus, altered cortisol action occurs not only in obesity and hypertension but also in glucose intolerance, and could therefore contribute to the link between these multiple cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466357     DOI: 10.1210/jc.2002-020048

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

Review 1.  Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome.

Authors:  P Putignano; F Pecori Giraldi; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

2.  Preliminary results of pinpoint plantar long-wavelength infrared light irradiation on blood glucose, insulin and stress hormones in patients with type 2 diabetes mellitus.

Authors:  Kenji Ryotokuji; Keisou Ishimaru; Kazuhiko Kihara; Yoshihisa Namiki; Nobumichi Hozumi
Journal:  Laser Ther       Date:  2013

3.  Quantification of cortisol for the medical diagnosis of multiple pregnancy-related diseases.

Authors:  Junna Zhang; Subash C B Gopinath
Journal:  3 Biotech       Date:  2020-01-07       Impact factor: 2.406

4.  Posttraumatic stress disorder and incidence of type-2 diabetes: a prospective twin study.

Authors:  Viola Vaccarino; Jack Goldberg; Kathryn M Magruder; Christopher W Forsberg; Matthew J Friedman; Brett T Litz; Patrick J Heagerty; Grant D Huang; Theresa C Gleason; Nicholas L Smith
Journal:  J Psychiatr Res       Date:  2014-06-09       Impact factor: 4.791

Review 5.  Impairment of Arterial Compliance in Cushing's Syndrome.

Authors:  Pier Paolo Bassareo; Angela Maria Zedda; Giuseppe Mercuro
Journal:  Eur Endocrinol       Date:  2014-08-28

6.  11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics.

Authors:  Thekkepat C Sandeep; Joyce L W Yau; Alasdair M J MacLullich; June Noble; Ian J Deary; Brian R Walker; Jonathan R Seckl
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-07       Impact factor: 11.205

Review 7.  11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.

Authors:  T M Stulnig; W Waldhäusl
Journal:  Diabetologia       Date:  2003-12-03       Impact factor: 10.122

Review 8.  PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

Authors:  Gary Landreth; Qingguang Jiang; Shweta Mandrekar; Michael Heneka
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 9.  Role of the hypothalamic-pituitary-adrenal axis in developmental programming of health and disease.

Authors:  Fuxia Xiong; Lubo Zhang
Journal:  Front Neuroendocrinol       Date:  2012-11-27       Impact factor: 8.606

10.  Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study.

Authors:  Rebecca M Reynolds; Mark W J Strachan; Javier Labad; Amanda J Lee; Brian M Frier; F Gerald Fowkes; Rory Mitchell; Jonathan R Seckl; Ian J Deary; Brian R Walker; Jackie F Price
Journal:  Diabetes Care       Date:  2010-01-22       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.